Prognostic impact of carcinoembryonic antigen in 1822 surgically treated esophageal squamous cell carcinoma: multi-institutional study of the Japan Esophageal Society.


Journal

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
ISSN: 1442-2050
Titre abrégé: Dis Esophagus
Pays: United States
ID NLM: 8809160

Informations de publication

Date de publication:
14 Dec 2022
Historique:
received: 09 02 2022
revised: 27 04 2022
pubmed: 7 6 2022
medline: 17 12 2022
entrez: 6 6 2022
Statut: ppublish

Résumé

Previous studies have evaluated the clinicopathological significance of carcinoembryonic antigen (CEA) of esophageal cancer in relatively small numbers of patients. Therefore, this study aimed to clarify the prognostic significance of CEA in 1822 patients with esophageal squamous cell carcinoma (SCC). Based on the Japanese Esophageal Society nationwide multi-institutional retrospective study, a total of 1,748 surgically treated ESCC from 15 hospitals were enrolled to evaluate prognostic impact of preoperative CEA values. Among them, 605 patients were categorized to up-front surgery group, and 1,217 patients were categorized to neoadjuvant therapy group. The CEA threshold for positivity was 3.7 ng/ml. The clinicopathological and prognostic impact of CEA was evaluated by univariate and multivariate analysis in each treatment modality groups. In total, the CEA positive rate was 25.8% (470/1822). CEA-positive status was significantly associated with distant metastasis (P = 0.004) but not associated with other factors. CEA-positive status was associated with poor overall survival (P < 0.001) in univariate analysis as well as multivariate analysis (P = 0.003). CEA was an independent prognostic determinant of overall survival in esophageal SCC. Based on the subgroup analysis, regardless of the treatment modality, patients with high pretreatment CEA showed poor overall survival.

Sections du résumé

BACKGROUND BACKGROUND
Previous studies have evaluated the clinicopathological significance of carcinoembryonic antigen (CEA) of esophageal cancer in relatively small numbers of patients. Therefore, this study aimed to clarify the prognostic significance of CEA in 1822 patients with esophageal squamous cell carcinoma (SCC).
METHODS METHODS
Based on the Japanese Esophageal Society nationwide multi-institutional retrospective study, a total of 1,748 surgically treated ESCC from 15 hospitals were enrolled to evaluate prognostic impact of preoperative CEA values. Among them, 605 patients were categorized to up-front surgery group, and 1,217 patients were categorized to neoadjuvant therapy group. The CEA threshold for positivity was 3.7 ng/ml. The clinicopathological and prognostic impact of CEA was evaluated by univariate and multivariate analysis in each treatment modality groups.
RESULTS RESULTS
In total, the CEA positive rate was 25.8% (470/1822). CEA-positive status was significantly associated with distant metastasis (P = 0.004) but not associated with other factors. CEA-positive status was associated with poor overall survival (P < 0.001) in univariate analysis as well as multivariate analysis (P = 0.003).
CONCLUSIONS CONCLUSIONS
CEA was an independent prognostic determinant of overall survival in esophageal SCC. Based on the subgroup analysis, regardless of the treatment modality, patients with high pretreatment CEA showed poor overall survival.

Identifiants

pubmed: 35661884
pii: 6601990
doi: 10.1093/dote/doac029
pii:
doi:

Substances chimiques

Carcinoembryonic Antigen 0
Antigens, Neoplasm 0
Serpins 0
Biomarkers, Tumor 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : JSPS
ID : JP16K10520

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Takashi Suzuki (T)

Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo 142-8541, Japan.

Satoshi Yajima (S)

Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo 142-8541, Japan.

Akihiko Okamura (A)

Department of Gastroenterological Surgery, Gastroenterology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Naoya Yoshida (N)

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8555, Japan.

Yusuke Taniyama (Y)

Department of Digestive Surgery, Tohoku University Graduate School of Medicine, Miyagi 980-8574, Japan.

Kentaro Murakami (K)

Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 263-8522, Japan.

Yu Ohkura (Y)

Department of Gastroenterological Surgery, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo 105-8470, Japan.

Yasuaki Nakajima (Y)

Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.

Koichi Yagi (K)

Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.

Takashi Fukuda (T)

Department of Gastroenterological Surgery, Saitama Cancer Center Hospital, Saitama 362-0806, Japan.

Ryo Ogawa (R)

Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Aichi 467-8601, Japan.

Isamu Hoshino (I)

Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba 260-8717, Japan.

Chikara Kunisaki (C)

Department of Surgery, Gastroenterological Center, Yokohama City University, Kanagawa 236-0004, Japan.

Kosuke Narumiya (K)

Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.

Yasuhiro Tsubosa (Y)

Division of Esophageal Surgery, Shizuoka Cancer Center, Shizuoka 411-8777, Japan.

Kazuhiko Yamada (K)

Department of Surgery, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.

Hideaki Shimada (H)

Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo 142-8541, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH